Daniel Evans

Below are recent executive appointments from the past few days across the  #Biotech, #CRO & #Pharma industry. 👨‍🔬 👩‍🔬 ➖ Altay Therapeutics Australia have appointed Jim Breitmeyer as their new CEO.✅ ➖ Kinaset Therapeutics have appointed Anesa Moyer as their new VP, Clinical Operations.✅ ➖ Autobahn Therapeutics, Inc. have appointed Jason Harris as their new CSO.✅ ➖ Ray Therapeutics, Inc. have appointed Michael Murtagh as their new CRO.✅ ➖ Soley Therapeutics have appointed Roya Nawabi as their new VP, Clinical Operations.✅ ➖ Tenvie Therapeutics have appointed Don O'Sullivan as their CBO.✅ ➖ Aquestive Therapeutics have appointed Matthew Greenhawt as their new CMO.✅ ➖ EyePoint have appointed Mike Campbell as their new CCO.✅ ➖ GenSight Biologics have appointed Fang Li, PhD RAC as their new CRO & CQO.✅ ➖ Caidya have appointed Michael Clay as their new COO.✅ ➖ Sana Biotechnology, Inc. have appointed Brian Piper as their new CFO.✅ ➖ CNS Pharmaceuticals, Inc. have appointed Dylan W. as their new CBO.✅ ➖ Galderma have appointed Luigi La Corte as their new CFO.✅ ➖ Longeveron have appointed Steve Willard as their new CEO.✅ ➖ Artios have appointed Caryn Barnett as their new VP, Clinical Operations.✅ Huge congratulations to all these incredible leaders from myself & everyone at Elixir Associates. 👏 👏 👏 #Appointments #Leaders #Executive #Elixir #Leadership #Hiring #News #DrugDevelopment #Pharma #LifeSceinces #Biotech #Bio #Therapeutics  #Staffing #Recruitment #ClinicalDevelopment #ClinicalResearch #Science

25

𝐒𝐂𝐄 | 𝐓𝐡𝐞 𝐒𝐞𝐜𝐫𝐞𝐭 𝐖𝐞𝐚𝐩𝐨𝐧 𝐓𝐫𝐚𝐧𝐬𝐟𝐨𝐫𝐦𝐢𝐧𝐠 𝐏𝐡𝐚𝐫𝐦𝐚 & 𝐁𝐢𝐨𝐭𝐞𝐜𝐡 💻   𝘞𝘩𝘺 𝘵𝘩𝘦 𝘚𝘵𝘢𝘵𝘪𝘴𝘵𝘪𝘤𝘢𝘭 𝘊𝘰𝘮𝘱𝘶𝘵𝘪𝘯𝘨 𝘌𝘯𝘷𝘪𝘳𝘰𝘯𝘮𝘦𝘯𝘵 (𝘚𝘊𝘌) 𝘐𝘴 𝘉𝘦𝘤𝘰𝘮𝘪𝘯𝘨 𝘢 𝘚𝘵𝘳𝘢𝘵𝘦𝘨𝘪𝘤 𝘈𝘴𝘴𝘦𝘵!   𝐅𝐫𝐨𝐦 𝐓𝐞𝐜𝐡𝐧𝐢𝐜𝐚𝐥 𝐓𝐨𝐨𝐥 𝐭𝐨 𝐒𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐜 𝐃𝐢𝐟𝐟𝐞𝐫𝐞𝐧𝐭𝐢𝐚𝐭𝐨𝐫 In today’s fast-paced clinical development environment, the SCE has evolved from a back-office necessity to a key competitive advantage. Modern pharma and biotech teams aren’t just running stats — they need platforms that deliver: 🔹 End-to-end traceability from data ingestion to regulatory-ready outputs 🔹 Scalable, cloud-native computation for genomics, RWD, imaging, and complex trials 🔹 Robust validation and compliance frameworks (GxP, global regulations) 🔹 Seamless collaboration across statisticians, data scientists, and cross-functional teams 🔹 Automation and reproducibility to reduce bottlenecks under tight timelines   𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲 𝐋𝐞𝐚𝐝𝐞𝐫𝐬 Several organizations are making major investments to modernize their SCE and analytics infrastructure:   AstraZeneca | Leveraging multiple cloud platforms for genomics and bioinformatics, enabling rapid, high-throughput analytics. Eli Lilly and Company | Partnered with NVIDIA to build a supercomputer, signaling the move toward AI/ML-enabled, compute-heavy drug development. IQVIA | Combining cloud-based analytics and data management to offer scalable, regulated SCE services to biotech and pharma globally. Clinical-data analytics providers | Instem, Oracle, Medidata Solutions, Veeva Systems, and SAS are scaling up cloud-based clinical-trial and real-world-data platforms that underpin SCE - like functionality (data integration, analytics, regulatory compliance, trial management   𝐖𝐡𝐲 𝐈𝐭 𝐌𝐚𝐭𝐭𝐞𝐫𝐬 A modern SCE isn’t just a computation engine — it’s a cornerstone of speed, quality, and trust. When implemented well, it enables: ✅ Clean, auditable, submission-ready outputs ✅ Reproducible and collaborative analytics workflows ✅ Faster insights from complex pipelines (genomics, imaging, AI/ML modeling, adaptive trials)   𝐓𝐡𝐞 𝐁𝐨𝐭𝐭𝐨𝐦 𝐋𝐢𝐧𝐞 Investing in a robust, scalable, and compliant SCE positions organizations to win in operational efficiency, R&D agility, and long-term competitiveness.   💬 𝐂𝐨𝐦𝐦𝐮𝐧𝐢𝐭𝐲 𝐐𝐮𝐞𝐬𝐭𝐢𝐨𝐧: How is your organization evolving its SCE? What challenges or gains have you seen?

9

1 Comment

“This transaction brings together clinically validated IP, EU commercial infrastructure, and manufacturing scale under one platform. We are building a capital-efficient engine to deliver next-generation formulations of CannEpil® and CimetrA® – at scale, with speed, and with enduring IP protection. It positions Argent to expand globally while strengthening our core pipeline.”

7

1 Comment

Drawing on our experience as Australia’s largest CRO, Novotech is joining the Australian delegation across the U.S. East Coast to share why Australia remains a high-performance environment for early-phase clinical trials. #ClinicalTrials #EarlyPhase #AustralianAdvantage

20